PHR

AI Memo

Phreesia

As of 2026-09-08/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

Q2 FY2027 results and reaffirmed outlook • 2026-09-02

Base target: $14 / p=50% prob

Biggest risk

Network Solutions visibility remains limited, particularly in the second half of the year. The business also faces pricing pressure, competition, restructuring execution risk, and continued debt obligations. The packet does not provide a verified consensus comparison or complete post-print analyst revision set.

Invalidation

Break below $9 or thesis failure.

What would change my mind?

Revenue, client count, revenue per client, adjusted EBITDA, and free cash flow all improved year over year, while management maintained FY2027 guidance and reduced debt. AccessOne and ProviderConnect could add growth if adoption scales.

Research note

Recommendation

—

Confidence

medium

As of

2026-09-08

Base target

$14

p=50%

Bull target

$17

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Network Solutions visibility and execution risk
AccessOne and ProviderConnect monetization
Revenue, client count, revenue per client, adjusted EBITDA, and free cash flow all improved year over year, while management maintained FY2027 guidance and reduced debt.

BearKey bullets

Competition from electronic health-record vendors and uncertain adoption of newer products could constrain client and revenue growth.
Network Solutions revenue forecasting has increased variability, especially in the second half of FY2027.
[#SEC-8K-2026-09-02]

WatchKey bullets

Q2 FY2027 results and reaffirmed outlook

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $14 (p=50%)

Target spread vs base: +22% / -37%

Scenario probabilities

Bull Target: $17 (p=25%)Base Target: $14 (p=50%)Bear Target: $9 (p=25%)

Commentary

The earnings follow-up is mixed: operating metrics, profitability, cash flow, debt reduction, and guidance were constructive, but forward visibility in Network Solutions remains limited. Social coverage and a complete post-print analyst-revision set are unavailable in the packet, so confidence remains moderate rather than high. The $10.94 anchor price is dated September 4, 2026.

As of 2026-09-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Network Solutions visibility and execution risk
AccessOne and ProviderConnect monetization

Scenarios

Bull Target (Scenario probability)

$17 / p=25% prob

Base Target (Scenario probability)

$14 / p=50% prob

Bear Target (Scenario probability)

$9 / p=25% prob

Analysis 2026-09-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-02
Q2 FY2027 results and reaffirmed outlook
Phreesia reported Q2 revenue of $129.5 million, up 10% year over year, adjusted EBITDA of $32.9 million, positive free cash flow of $13.8 million, and debt principal reduction of more than $23 million. FY2027 revenue and adjusted EBITDA outlooks were maintained at $510-$520 million and $125-$135 million, respectively. [#SEC-8K-2026-09-02]
Prob 100.00% • Move -8.00% • Priced-in 100.00%

Short-term Catalysts

Next few weeks

Network Solutions visibility and execution risk
2026-12-07
The company stated that Network Solutions revenue forecasting has greater variability, particularly in the second half of fiscal 2027. This creates downside risk to the maintained outlook if client adoption, pricing, or campaign activity underperforms. [#SEC-8K-2026-09-02]
Prob 45% • Move -12% • Priced-in 55%

Long-term Catalysts

Months to a year

AccessOne and ProviderConnect monetization
2027-09-08
Management identified AccessOne and ProviderConnect as products expected to drive future growth. FY2027 revenue guidance assumes approximately $37 million from AccessOne, while ProviderConnect remains an emerging Network Solutions opportunity. Execution and adoption remain unproven. [#SEC-8K-2026-09-02]
Prob 55% • Move 20% • Priced-in 35%

Risks

Competition from electronic health-record vendors and uncertain adoption of newer products could constrain client and revenue growth.
Network Solutions revenue forecasting has increased variability, especially in the second half of FY2027. [#SEC-8K-2026-09-02]
Phreesia had $61 million of borrowings outstanding under its credit facility as of July 31, 2026, despite reducing debt principal by more than $23 million during the quarter. [#SEC-8K-2026-09-02]
Subscription pricing moderation and deductible-reset seasonality may pressure near-term revenue growth.
The restructuring plan eliminates approximately 220 positions and carries expected charges of approximately $10 million, creating execution and service-delivery risk. [#SEC-8K-2026-09-02]

Peers

Symbol	Summary
ANGO	Same-sector and similar market-cap reference, but its medical-device business is not a direct match for Phreesia's healthcare-services, payments, and software model.
KIDS	Small-cap health-care equipment reference with limited business-model comparability; useful only for broad sector and size context.
ABT	Large diversified medtech benchmark, not a direct operating peer; valuation and scale comparisons should be heavily discounted.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-08

Loading AI feed…

Symbol

Summary

ANGO

Same-sector and similar market-cap reference, but its medical-device business is not a direct match for Phreesia's healthcare-services, payments, and software model.

KIDS

Small-cap health-care equipment reference with limited business-model comparability; useful only for broad sector and size context.

ABT

Large diversified medtech benchmark, not a direct operating peer; valuation and scale comparisons should be heavily discounted.